MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline
MapleStory , the iconic free-to-play global MMORPG from Nexon, has launched Neo: Light’s Wrath, Part Two of the massive summer content update that offers all new desert area, Hotel Arcus, offering new quests available to players level 270 and above. The Neo: Light’s Wrath update also adds the new Boss Seren and continues the Neo Castle, Tera Burning and Burning World Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005292/en/
MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline (Photo: Business Wire)
Hidden secrets of the ancient gods will be unveiled in the Hotel Arcus desert area which has opened for players who have reached Level 270 and have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest. Following clues from the ancient gods will reveal the mysteries of the Hotel Arcus, offering a series of quests that will reward players with the Sacred Symbol: Arcus upon completion. After all Hotel Arcus quests are completed players can perform daily quests for Archelon in the Hotel Arcus Saloon that will reward Sacred Symbol: Arcus.
With the battle at Cernium at its end, Seren has emerged as god incarnate, wielding the power of the ancient gods. Players level 265 who have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest are able to test their strength against the powerful new boss Seren by entering a special portal in the Cernium Royal Palace Main Hall. By defeating Seren, players have the chance to earn Mitra’s Nodestone and Mitra’s Rage Emblem, part of the Pitched Boss Set. Mitra’s Nodestone unlocks the Solar Crest skill when used and Mitra’s Rage Emblem provides +40 primary stat/secondary stat for your class and +5 Attack/Magic Attack. Mitra’s Rage is tradable until equipped and can be equipped at level 200.
The Neo: Light’s Wrath Update continues the Neo Castle and Tera Burning and Burning World Events:
Neo Castle Event: Neo Castle is an area shrouded in mystery and was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events and mini-games including new ways to earn NEO currency with the following features and shops available:
- Neo Stone Shop: Players can exchange Neo Stones for a variety of items that can be used to enhance equipment and boost character growth
- Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop: Neo Cores can be collected by defeating bosses and can be used to purchase a variety of enhancement items
- Neo Meso Shop: The Meso shop is stocked full of useful items and cosmetic items that can be purchased using Mesos
Burning World and Tera Burning Plus: Burning World and Tera Burning Plus events continue to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon if your Tera Burning Plus character reaches Lv. 220. Burning World Leap will begin August 25 and characters Lv. 150 and above will be able to leap to any non-Reboot world in their region.
To learn more about MapleStory , please visit http://maplestory.nexon.net
Assets - Neo: Light’s Wrath Video - Artwork
Social Media: TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005292/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom